1-(4-硝基苯)-5-(三氟甲基)-1H-吡唑-4-羰酸 | 142818-03-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-硝基苯)-5-(三氟甲基)-1H-吡唑-4-羰酸
• 中文别名: 1-(4-硝基苯基)-5-(三氟甲基)吡唑-4-羧酸；1-(4-硝基苯基)-5-(三氟甲基)-1H-吡唑-4-羧酸；1-(4-硝基苯)-5-(三氟甲基)-1H-吡唑-4-羰酸,97%
• 英文名称: 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-(4-nitrophenyl)-5-(trifluoromethyl)pyrazole-4-carboxylic acid
• CAS: 142818-03-9
• 化学式: C₁₁H₆F₃N₃O₄
• mdl: MFCD00173867
• 分子量: 301.182
• InChiKey: FGHNILTUXGDLKS-UHFFFAOYSA-N

物化性质

• 熔点：
  199-203 °C
• 沸点：
  452.6±45.0 °C(Predicted)
• 密度：
  1.65±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，也未有已知的危险反应。请避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 危险品标志：
  Xn,Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933199090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 1-(4-Nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-
carboxylic acid
CAS-No. : 142818-03-9
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C11H6F3N3O4
Molecular Weight : 301,18 g/mol
Component Concentration
1-(4-Nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
CAS-No. 142818-03-9 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 199 - 203 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,673
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1-(4-硝基苯)-5-(三氟甲基)-1H-吡唑-4-羰酸 在 氯化亚砜 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 1-(4-aminophenyl)-N-ethyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  [EN] TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE POTENTIELS DE RÉCEPTEUR TRANSITOIRE CANONIQUE 3 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本文提供的是化合物、包含这些化合物的药物组合物，以及使用这些化合物治疗与TRPC3活性相关的疾病或疾病的方法。

  公开号：

  WO2022081573A1
• 作为产物：
  描述：

  乙氧基-2-亚甲基三氟乙酰乙酸乙酯 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 14.0h， 生成 1-(4-硝基苯)-5-(三氟甲基)-1H-吡唑-4-羰酸
  参考文献：
  名称：

  [EN] TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE POTENTIELS DE RÉCEPTEUR TRANSITOIRE CANONIQUE 3 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本文提供的是化合物、包含这些化合物的药物组合物，以及使用这些化合物治疗与TRPC3活性相关的疾病或疾病的方法。

  公开号：

  WO2022081573A1

文献信息

• Tertiary‐Amine‐Initiated Synthesis of Acyl Fluorides from Carboxylic Acids and CF ₃ SO ₂ OCF ₃
  作者：Hai‐Xia Song、Ze‐Yu Tian、Ji‐Chang Xiao、Cheng‐Pan Zhang

  DOI：10.1002/chem.202003756

  日期：2020.12.9

  A convenient method for deoxyfluorination of aromatic and aliphatic carboxylic acids with CF3SO2OCF3 in the presence of a suitable base at room temperature has been developed. The reaction allows a straightforward access to a variety of acyl fluorides and proves that CF3SO2OCF3 is an effective deoxyfluorination reagent for carboxylic acids. The method features simplicity, expeditiousness, high efficiency

  已经开发了在室温下在合适的碱存在下用CF 3 SO 2 OCF 3将芳族和脂族羧酸脱氧氟化的简便方法。该反应可直接获得各种酰基氟，并证明CF 3 SO 2 OCF 3是一种有效的羧酸脱氧氟化剂。该方法的特点是简单，快速，高效，易于处理，对官能团的耐受性强，底物范围广，产品收率高，许多胺引发剂的相容性，使用环境友好的试剂以及轻松去除副产物。该反应代表了三氟甲基三氟甲磺酸盐首次用作氟化试剂。
• Direct Synthesis of Acyl Fluorides from Carboxylic Acids with the Bench-Stable Solid Reagent (Me₄N)SCF₃
  作者：Thomas Scattolin、Kristina Deckers、Franziska Schoenebeck

  DOI：10.1021/acs.orglett.7b02516

  日期：2017.11.3

  A convenient, highly efficient, and selective transformation of aliphatic and aromatic carboxylic acids to acyl fluorides is reported. In contrast to established approaches that require toxic or volatile additives and base and reaction control (i.e., cooling, slow addition), this protocol allows for a straightforward access to various R-COF entities upon direct reaction with the bench-stable, solid

  据报道，将脂肪族和芳香族羧酸方便，高效且选择性地转化为酰基氟。与需要有毒或挥发性添加剂以及碱和反应控制（即冷却，缓慢添加）的既定方法相比，该方案可以在与稳定的固体试剂直接反应后直接访问各种R-COF实体（在室温下为Me 4 N）SCF 3。该方法无碱和无添加剂，与后期合成应用程序兼容，具有较高的官能团耐受性，并且可通过过滤轻松纯化目标化合物。
• Acylated indanyl amines and their use as pharmaceuticals
  申请人：——

  公开号：US20030055093A1

  公开（公告）日：2003-03-20

  The present invention relates to acylated indanyl amines according to the general formula (I) 1 wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B is CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式（I）中的酰化的茚基胺，其中R1-R4具有描述中给出的含义，A为CH2、CHOH或CH—（C1-C3-烷基），B为CH2或CH—（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物在上调内皮型一氧化氮合酶（eNOS）方面有用，因此可能用于制造用于治疗心血管疾病、稳定或不稳定心绞痛、冠心病、普林兹梅塔心绞痛、急性冠状综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、骨质疏松症、记忆力受限、学习能力受限，或用于降低绝经后妇女或口服避孕药后心血管风险。
• [EN] TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE POTENTIELS DE RÉCEPTEUR TRANSITOIRE CANONIQUE 3 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV TENNESSEE RES FOUND

  公开号：WO2022081573A1

  公开（公告）日：2022-04-21

  Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with TRPC3 activity.

  本文提供的是化合物、包含这些化合物的药物组合物，以及使用这些化合物治疗与TRPC3活性相关的疾病或疾病的方法。
• ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20070082897A1

  公开（公告）日：2007-04-12

  The present invention relates to acylated indanyl amines according to the general formula (I) wherein R 1 —R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B is CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及通式（I）的酰化吲哚基胺，其中R1-R4具有描述中给出的含义，A为CH2，CHOH或CH-（C1-C3-烷基），B为CH2或CH-（C1-C3-烷基），而R5为芳基或杂芳基基团，可能被描述中列出的取代基所取代。这些化合物有助于上调内皮型一氧化氮合酶（eNOS），因此可能用于制造用于治疗心血管疾病、稳定或不稳定型心绞痛、冠心病、普林兹梅塔尔心绞痛、急性冠状动脉综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞症、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后的内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病或糖尿病并发症、肾病或视网膜病变、血管生成、支气管哮喘、慢性肾衰竭、肝硬化、骨质疏松症、受限制的记忆表现、受限制的学习能力或降低绝经后妇女或口服避孕药后的心血管风险。